MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Qiagen and Eli Lilly Partner to Develop Alzheimer's Risk Diagnostic Panel

NextEdge Admin

06 Sep 2024

2 min 8 sec

Qiagen announced a collaboration with Eli Lilly to develop an in vitro diagnostic assay designed to detect genotypes associated with Alzheimer's disease risk. While financial details were not disclosed, Qiagen revealed that the multiplex PCR panel will be created for its QiaStat-Dx testing system, marking the first commercially available in vitro diagnostic (IVD) test of its kind.

The QiaStat-Dx panel will identify APOE2, APOE3, and APOE4 genotypes, which play a critical role in assessing Alzheimer's disease risk. The APOE4 genotype, in particular, is known to increase the likelihood of developing Alzheimer's earlier in life, especially when two copies of the genotype are present.

Jonathan Arnold, VP and head of translational science and precision diagnostics at Qiagen, stated that the goal of the assay is to provide precise APOE genotyping, helping to inform treatment decisions and offering valuable insights throughout the diagnostic process for Alzheimer's patients.

Anthony Sireci, Eli Lilly’s head of diagnostics development, emphasized the importance of high-quality, accurate, and accessible diagnostic tests for clinical use. He highlighted Qiagen's expertise in diagnostic assay development and its global reach as key reasons for partnering with them to generate data for the APOE test.

This collaboration represents Qiagen’s first publicly disclosed neurodegenerative disease clinical project for the QiaStat-Dx system, adding to previous partnerships with Neuron23 and Helix.